Good Q1 actually, Forecasted revenue 25m+ for FY21 and only 118m marketcap shows good value in my book. They aren't burning much cash at all, and it's well worth it to spend on sales growth. Personally I think the negative perceptions of covid have weighed on this stock, along with people shifting funds to high-flying tech outside the healthcare sector. I'll be watching how Q2 comes along before investing, but this is certainly on my watchlist.
Ann: Q1 FY2021 Business Update and Appendix 4C, page-6
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
